C3 glomerulonephritis: a new category of glomerulonephritis with etiopathogenic implications
DOI:
https://doi.org/10.17533/udea.iatreia.17580Keywords:
alternative complement pathway, C3 glomerulonephritis, C3 glomerulopathy, renal diseaseAbstract
Introduction: Glomerulonephritis with only deposits of C3 (GN-C3) could involve alteration on the complement alternative pathway.
Objective: To describe retrospectively a series of GNC3 cases and to determine the frequency with which patients continue with renal alterations and/or hypocomplementemia.
Methods: The 22 cases of GN-C3 diagnosed between 2004 and 2012 at the Department of Pathology, Faculty of Medicine, University of Antioquia (Medellin, Colombia) were included. Their histological and clinical characteristics and their outcome were evaluated.
Results: 14 patients were children and 12 were males. Mean age was 13 years (range: 3-65). Ten presented as a nephritic syndrome, seven as a rapidly progressive GN, three as acute renal failure, one as chronic renal failure, and one as a nephrotic-nephritic syndrome. The C3 fraction of complement was low in 21 cases. All biopsies showed proliferative GN. There was complete remission in eight patients, persistent urinalysis alterations in four, chronic renal failure in six, five of them end-stage. No follow-up was done in four. In nine patients follow-up determination of C3 serum levels was done; in all of them they normalized between 1 to 3 months after biopsy.
Conclusions: GN-C3 can produce persistent or recurrent kidney alterations and end-stage renal disease. Long-term follow-up with repeated determinations of C3 is advisable.
Downloads
References
(1.) Schwartz MM, Korbet SM, Katz RS, Lewis EJ. Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis. Lupus. 2009 Mar;18(2):149–58.
(2.) Jennette J, Olson J, Schwartz M, Silva F. Heptinstall’s Pathology of the Kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
(3.) Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet. 2007 Mar;44(3):193–9.
(4.) Fakhouri F, Frémeaux-Bacchi V, Noël L-H, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol. 2010 Aug;6(8):494–9.
(5.) Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol. 2011 May;6(5):1009–17.
(6.) Servais A, Noël L-H, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey M-A, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012 Aug;82(4):454–64.
(7.) Larsen CP, Walker PD. Redefining C3 glomerulopathy: “C3 only” is a bridge too far. Kidney Int. 2013 Mar;83(2):331–2.
(8.) Gale DP, Maxwell PH. C3 glomerulonephritis and CFHR5 nephropathy. Nephrol Dial Transplant. 2013 Mar;28(2):282–8.
(9.) Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012 Nov;8(11):634–42.
(10.) Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012 Aug;82(4):465–73.
(11.) Haas M. Incidental healed postinfectious glomeru-lonephritis: a study of 1012 renal biopsy specimens examined by electron microscopy. Hum Pathol. 2003 Jan;34(1):3–10.
(12.) Sethi S, Fervenza FC, Zhang Y, Zand L, Meyer NC, Borsa N, et al. Atypical postinfectious glomerulo-nephritis is associated with abnormalities in the al-ternative pathway of complement. Kidney Int. 2013 Mar;83(2):293–9.
(13.) Sandhu G, Bansal A, Ranade A, Jones J, Cortell S, Markowitz GS. C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. Am J Kid-ney Dis. 2012 Dec;60(6):1039–43.
(14.) Vernon KA, Goicoechea de Jorge E, Hall AE, Fre-meaux-Bacchi V, Aitman TJ, Cook HT, et al. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis. 2012 Jul;60(1):121–5.
(15.) Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, et al. Toward a working defini-tion of C3 glomerulopathy by immunofluorescence. Kidney Int. 2014 Mar;85(2):450–6.
(16.) West CD, Witte DP, McAdams AJ. Composition of ne-phritic factor-generated glomerular deposits in mem-branoproliferative glomerulonephritis type 2. Am J Kidney Dis. 2001 Jun;37(6):1120–30.
(17.) Gewurz AT, Imherr SM, Strauss S, Gewurz H, Mold C. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol. 1983 Oct;54(1):253–8.
(18.) Frémeaux-Bacchi V, Weiss L, Demouchy C, May A, Palomera S, Kazatchkine MD. Hypocomplementae-mia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant. 1994 Jan;9(12):1747–50.
(19.) Chen Q, Müller D, Rudolph B, Hartmann A, Kuwertz-Bröking E, Wu K, et al. Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med. 2011 Dec 15;365(24):2340–2.
(20.) Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jo-nes M, et al. Causes of alternative pathway dysregula-tion in dense deposit disease. Clin J Am Soc Nephrol. 2012 Mar;7(2):265–74.
(21.) Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens. 2011 May;20(3):271–7.
(22.) Degn SE, Jensenius JC, Thiel S. Disease-causing muta-tions in genes of the complement system. Am J Hum Genet. 2011 Jun 10;88(6):689–705.
(23.) Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med. 2011;17(3-4):317–29.
(24.) Sarma JV, Ward PA. The complement system. Cell Tis-sue Res. 2011 Jan;343(1):227–35.
(25.) D’Agati VD, Bomback AS. C3 glomerulopathy: what’s in a name? Kidney Int. 2012 Aug;82(4):379–81.
(26.) Skerka C, Licht C, Mengel M, Uzonyi B, Strobel S, Zipfel PF, et al. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glo-merulonephritis: Indications for a disease spectrum and common pathogenic principles. Mol Immunol. 2009 Sep;46(14):2801–7.
(27.) Boyer O, Noël L-H, Balzamo E, Guest G, Biebuyck N, Charbit M, et al. Complement factor H deficien-cy and posttransplantation glomerulonephritis with isolated C3 deposits. Am J Kidney Dis. 2008 Apr;51(4):671–7.
(28.) Lorcy N, Rioux-Leclercq N, Lombard M-L, Le Pogamp P, Vigneau C. Three kidneys, two diseases, one antibo-dy? Nephrol Dial Transplant. 2011 Nov;26(11):3811–3.
(29.) Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, et al. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int. 2009 Jun;75(11):1230–4.
(30.) Gale DP, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet. 2010 Sep 4;376(9743):794–801.
(31.) Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol. 2013 Oct;28(10):1975–81.
(32.) Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy. Nephrol Dial Transplant. 2013 Jul;28(7):1685–93.
(33.) Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, et al. Pathology after eculizu-mab in dense deposit disease and C3 GN. J Am Soc Nephrol. 2012 Jul;23(7):1229–37.
(34.) Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012 May;7(5):748–56.
(35.) Vivarelli M, Pasini A, Emma F. Eculizumab for the treatment of dense-deposit disease. N Engl J Med. 2012 Mar 22;366(12):1163–5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2014 Iatreia
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
